Back to top
more

Clearside Biomedical (CLSD)

(Delayed Data from NSDQ)

$1.32 USD

1.32
47,712

+0.01 (0.92%)

Updated Apr 22, 2024 11:48 AM ET

After-Market: $1.42 +0.10 (7.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CLSD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Clearside Biomedical, Inc. [CLSD]

Reports for Purchase

Showing records 41 - 60 ( 273 total )

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

05/12/2022

Company Report

Pages: 5

1Q22 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 5.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

04/29/2022

Industry Report

Pages: 2

ARVO, the Global Ophthalmology Meeting Begins on Sunday, May 1st in Denver

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

03/29/2022

Company Report

Pages: 7

XIPERE Commercially Launched in the U.S.; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

03/14/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

03/11/2022

Company Report

Pages: 6

2021 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

03/11/2022

Company Report

Pages: 8

OASIS Expanded to Include Cohort 4, Positive Partner Program Updates

Provider: WEDBUSH SECURITIES INC.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

03/11/2022

Company Report

Pages: 6

4Q21 Update - Progress Highlights Market Inefficiencies & More to Come

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

03/06/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

02/14/2022

Industry Report

Pages: 12

Angio 2022: Keeping Safety First While Advancing Towards Extended Duration

Provider: WEDBUSH SECURITIES INC.

Analyst: ARGYRIDES A

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

01/27/2022

Industry Report

Pages: 7

Cash Balance and 2022 Catalysts For Our Biotech Coverage Universe

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

01/14/2022

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

01/14/2022

Industry Report

Pages: 4

BEST IDEAS LIST - Removing SAIL and MTTR

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

01/10/2022

Industry Report

Pages: 4

BEST IDEAS LIST - Removing SI

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

12/22/2021

Company Report

Pages: 6

Positive Data from Cohort 2 of Wet AMD trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

12/22/2021

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

12/22/2021

Company Report

Pages: 6

CLS-AX''s Safety Supports Continued Dose-Escalation in Wet AMD

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

12/21/2021

Company Report

Pages: 9

CLS-AX Heating Up in Time for Winter with Clean Safety & Dose Response

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

12/17/2021

Daily Note

Pages: 5

We are removing OPEN and WIX from the Best Ideas List due to our investment price discipline.

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

12/17/2021

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Clearside Biomedical, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

12/15/2021

Daily Note

Pages: 14

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party